Click here to submit Post PR News
Type 2 Diabetes: Boehringer Ingelheim India and Lupin Announce Strategic Co-marketing Agreement
Mumbai, October 13th, 2016: Boehringer Ingelheim and pharma major Lupin Limited (Lupin) today announced another strategic alliance to co-market Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India. Boehringer Ingelheim and Lupin had earlier signed a partnership for Co-Marketing →
0 Views : 1419
Sun Pharma reports Q4 & FY15 results
Mumbai, May 29, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for fourth quarter & full year ending March 31st, 2015. The financials for Q4FY15 and full year FY15 include the impact →
0 Views : 2165
GlaxoSmithKline Pharmaceuticals announces Q3 Results
November 07, 2014 GlaxoSmithKline Pharmaceuticals Limited announced its financial results for the third quarter ended September 30, 2014. The core Pharmaceuticals business grew by 20.4% for the quarter. Impact of the previous year National List of Essential Medicines (NLEM) price →
0 Views : 1574
Piramal Imaging Announces EU Approval of NeuraCeqTM (florbetaben 18F) for PET Imaging of Beta-Amyloid Neuritic Plaque Density in the Brain
On February 24, 2014, Piramal Imaging announced that NeuraCeq™ has received marketing authorization from the European Commission. NeuraCeq™ is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with →
0 Views : 1516
Cadila Pharmaceuticals ties up with NovaSAID of Sweden
On January 13, 2014, Cadila Pharmaceuticals announced it strategic partnership with NovaSAID AB to develop new treatments for inflammation and pain in conditions such as rheumatoid arthritis. NovaSAID is a company in Karolinska Development’s portfolio. The companies will collaborate around →
0 Views : 1229
Sun Pharma reports a strong Q3
On February 13, 2014, Sun Pharmaceutical Industries Ltd. reported financials for third quarter of 2013. The highlights of Q3 FY14 consolidated financials are as follows – 1) Net sales / Income from operations at Rs. 4287 crores, a growth of →
0 Views : 1129
Piramal Enterprises acquires the brand CALADRYL® in India
On November 1st, 2013, Piramal Enterprises announced that it has acquired the brand CALADRYL® in India from Valeant Pharmaceuticals International, Inc. This acquisition enables Piramal Enterprises to widen its product portfolio in the skin care segment. →
0 Views : 1398
Cipla declares Q3 results
Pharmaceutical company Cipla Ltd. declared a Q3 net profit of Rs. 284 crores. It is down 17% from Rs. 340 crore registered in the corresponding period last year. →
0 Views : 1459
Ranbaxy & Teva settle claims
Ranbaxy Laboratories and Teva Pharmaceuticals settled claims that stated that the two drug makers unlawfully restricted competition. It was settled with the New York Attorney General. The two drug leaders will pay he New York state $300,000 and have agreed →
0 Views : 1438
GSK announces Rs. 864 crore pharmaceutical manufacturing unit in India
On 14th November, 2013, GlaxoSmithKline (GSK) announced that it would invest Rs. 864 crore [£85million] in setting up a new pharmaceutical manufacturing facility in India. The location of the new factory is yet to be finalized. The lead site is →
0 Views : 1418
